On April 26, 2019 (U.S. EST) Elanco Animal Health Inc. (U.S., Elanco) announced that it signed an agreement to acquire Aratana Therapeutics (U.S., Aratana) in a stock transaction valued at $245 million. Galliprant® (grapiprant/AT-001), the EP4 receptor antagonist owned by AskAt and currently co-marketed by Aratana and Elanco, featured prominently in the transaction. Described by both Elanco and Aratana as a first-of-its-kind canine NSAID for osteoarthritis, Galliprant® is now dispensed by more clinics in the U.S. than another oral NSAID.